Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer

NCT00121095 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: Samarium Sm-153 lexidronam + Docetaxel

Sponsor

Cytogen Corporation